Effects of the AMPA antagonist ZK 200775 on visual function: a randomized controlled trial.

ABSTRACT:

Background

ZK 200775 is an antagonist at the alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor and had earned attention as a possible neuroprotective agent in cerebral ischemia. Probands receiving the agent within phase I trials reported on an alteration of visual perception. In this trial, the effects of ZK 200775 on the visual system were analyzed in detail.

Methodology

In a randomised controlled trial we examined eyes and vision before and after the intravenous administration of two different doses of ZK 200775 and placebo. There were 3 groups of 6 probands each: Group 1 recieved 0.03 mg/kg/h, group 2 0.75 mg/kg/h of ZK 200775, the control group received 0.9% sodium chloride solution. Probands were healthy males aged between 57 and 69 years. The followi

SUBMITTER: Bergholz R 

PROVIDER: S-EPMC2920815 | biostudies-literature | 2010 Aug

REPOSITORIES: biostudies-literature